3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2009 Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Ther 16:246-255
2. 2009 In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec 71:1-5
3. 2009 Cytosine Deaminase/5-fluorocytosine Molecular Cancer Chemotherapy. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools, AM Fialho, AM Chakrabarty (eds.) John Wiley & Sons, Inc
4. 2009 Cancer Gene Therapy Principles of Cancer Biotherapy, 5th Edition, RK Oldham, RO Dillman (eds.) Springer Publishers
5. 2009 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model Int J Gynecol Cancer 19:814-819
6. 2009 Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1 Mol Pharmacol 76:81-90
7. 2009 Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15:4058-4065
8. 2009 Altered expression of 15-hydroyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer J Immunol 182:7548-7557
9. 2009 Preclinical data and clinical utilization of monoclonal antibodies in epithelial ovarian cancer Gynecol Oncol 113:384-390
10. 2009 Monoclonal antibodies in the treatment of pancreatic cancer Immunotherapy 1:223-239
11. 2008 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model Gynecol Oncol 108:591-597
12. 2008 Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 14:2180-2189
13. 2008 Radioimmunotherapy Targeting TAG-72 for Ovarian Cancer Antibody Therapy of Gynecological Cancer, J Berek, G Coukos (eds.) Summit Communications,
14. 2008 Enhancement of glioma radiation therapy and chemotherapy response with targeted antibody therapy against death receptor 5. Response, Letter to the editor Int J Radiat Oncol Biol Phys 72:1274
15. 2008 Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83:179-189
16. 2008 Early therapy evaluation of combined anti-DR5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion weighted magnetic resonance imaging. Cancer Res 68:8369-8376
17. 2008 Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Mol Cancer Ther 7:2845-2854
18. 2008 Molecular targeted therapies for pancreatic cancer Am J Surg 196:430-441
19. 2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 26, 4314-4319
20. 2008 Enhancement of glioma radiation therapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 71:507-516
21. 2008 Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 57:634-641
22. 2007 Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma Gene Ther 14:1111-1119
23. 2007 High resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 6:866-875
24. 2007 Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141:464-469
25. 2007 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model Gynecol Oncol 105:291-298
26. 2007 Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response Ann Surg Oncol 14:2150-2158
27. 2007 TRAIL receptor antibodies as a potential cancer treatment Future Oncol 3:405-409
28. 2007 ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib Cancer Biol Ther 6:548-554
29. 2007 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers Gynecol Oncol 106:614-621
30. 2007 Combination treatment with TRA-8 anti-death receptor-5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer Clin Cancer Res 13:5535s-5543s
31. 2007 Brief overview of pre-clinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer Clin Cancer Res 13:5643s-5645s
32. 2007 EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients J Surg Res 143:20-26
33. 2007 TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth Mol Cancer Ther 6:3198-3207
34. 2007 Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. Cancer Biol Ther 6:1396-1402
35. 2006 Oncolytic HSV-1 for the treatment of brain tumours Herpes 13:66-71
36. 2006 Pretargeted radioimmunotherapy Int J Radiat Oncol Biol Phys 66:S57-59
37. 2006 Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo J Gastrointest Surg 10:1291-1300
38. 2006 Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma J Mol Diagn 8:76-83
39. 2006 Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity Cancer Gene Ther 13:203-214
40. 2006 Gene delivery and gene therapy of prostate cancer Expert Opin Drug Deliv 3:37-51
41. 2006 Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 101:46-54
42. 2006 TRAIL receptor-targeted therapy Future Oncol 2:493-508
43. 2006 Interaction of Chemotherapy and Radiation Clinical Radiation Oncology, 2nd Edition, Gunderson LL, Tepper JE (eds.) Churchill Livingstone
44. 2006 Radioimmunotherapy of Solid Tumors Nuclear Medicine, R.E. Henkin et al. (eds.), Mosby-Year Book, Inc., St. Louis, MO, pp. 1624-1632
45. 2006 Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Res 66:8520-8528
46. 2005 Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein Clin Cancer Res 11:8180-8185
47. 2005 The small heat shock protein aB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280:11059-11066
48. 2005 Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. Gene Ther 12:407-417
49. 2005 Radiotargeted gene therapy J Nucl Med 46:179S-186S
50. 2005 Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects. Clin Cancer Res 11:8773-8781
51. 2005 Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted Ch2 region Cancer Biother Radiopharm 20:502-513
52. 2004 Gene expression imaging with radiolabeled peptides. Ann Nucl Med 18:275-283
53. 2004 Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells J Gastrointest Surg 8:960-970
54. 2004 Adenovirus-mediated flt1-targeted proapoptotic gene therapy of human prostate cancer. Mol Ther 10:1059-1070
55. 2004 Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure Bioconjug Chem 15:1264-1274
56. 2004 Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int J Radiat Oncol Biol Phys 59:S2-S10
57. 2004 Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells Gene Ther 11:658-667
58. 2004 Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells Int J Radiat Oncol Biol Phys 58:950-958
59. 2004 Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs Semin Nucl Med 34:32-46
60. 2003 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery Bioconjug Chem 14:302-310
61. 2003 Combined External Beam Radiotherapy and Radioimmunotherapy Targeted Therapy for Cancer, K.N. Syrigos, K.J. Harrington (eds.) Oxford University Press, Oxford, England, pp. 76-91
62. 2003 Cancer Gene Therapy Principles of Cancer Biotherapy, 4th Edition, R.K. Oldham (ed.) Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 583-613
63. 2003 Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731-3741
64. 2003 Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 111:274-283
65. 2003 Three-dimensional dose model for the comparison of 177Lu-HuCC49∆CH2 and 177Lu-HuCC49 radioimmunotherapy in mice bearing intraperitoneal xenografts. Cancer Biother Radiopharm 18:239-247
66. 2003 Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway Oncogene 22: 2034-2044
67. 2003 An adenovirus encoding proapoptotic bax synergistically radiosensitizes malignant glioma Int J Radiat Oncol Biol Phys 55:1037-1050
68. 2003 Targeting of 125I-labeled B lymphocyte stimulator. Editorial J Nucl Med 44:434-436
69. 2002 Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus Radiology 223:417-425, 2002
70. 2002 De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent Bioconjug Chem 13:317-326
71. 2002 Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv Gene Ther 9:256-262
72. 2002 Rationales, evidence, and design considerations for fractionated radioimmunotherapy Cancer 94:1332-1348
73. 2002 Adenovirus-mediated transfer of Bax driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells Mol Ther 6:190-198
74. 2002 Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation Mol Cancer Ther 1:1139-1145
75. 2002 Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation Int J Radiat Oncol Biol Phys 54:1180-1193
76. 2002 Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas Cancer Res 62:773-780
77. 2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer 94:1264-1269
78. 2002 Targeted radiotherapy with [90Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector Cancer 94:1298-1305
79. 2002 188Rhenium-Labeled Trisuccin-∆Ch2HuCC49 as a Radioimmunotherapy Model in Nude Mice Tumor Targeting in Cancer Therapy, M. Pagé (ed.) Humana Press Inc., Totowa, NJ, pp. 257-276
80. 2002 Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem 301:189-199
81. 2002 Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent Bioconjug Chem 13:327-332
82. 2000 Radioimmunotherapy Clinical Radiation Oncology, L.L. Gunderson, J.E. Tepper (eds.) Churchill Livingstone, Philadelphia, pp. 283-299
83. 2000 Gene expression imaging with 111In- and 99mTc-labeled peptides of somatostatin receptors upregulated by adenovirus infection. Society of Nuclear Medicine Categorical and Continuing Education Handout Book
84. 2000 : Radiation to control gene expression. Editorial Gene Ther 7:1085-1086
85. 2000 Radionuclide Dosimetry and Radiotherapy of Cancer Radioimmunotherapy of Cancer, P.G. Abrams, A.R. Fritzberg (eds.) Marcel Dekker, Inc., New York, pp. 21-55
86. 1999 Mouse models for internal radiation dosimetry - Response, Letter to the editor J Nucl Med, 40:1970
87. 1999 In vitro binding and internalization of an indium-111 labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. M. Nicolini, U. Mazzi (eds.) Servizi Grafici Editoriali, Padova, 5:519-525
88. 1993 Dosimetry of Radiolabelled Antibody Therapy Monoclonal Antibodies 2: Applications in Clinical Oncology, A.A. Epenetos (ed.), Chapman and Hall Medical, London, pp. 421-428
89. 1993 Radioimmunotherapy of Human Malignancies Advances in Nuclear Oncology, D. Delbeke (ed.), Southeastern Chapter Society of Nuclear Medicine, Cincinnati, OH, 1993, VII-1 - VII-14.
90. 1991 Initial observations on the effect of pre-dosing on the delivery of 131I-labelled MB-1 MoAb to lymphoma xenografts Monoclonal Antibodies: Applications in Clinical Oncology, A.A. Epenetos (ed.), Chapman and Hall Medical, London, pp. 115-121
91. 1990 New Trends in the Use of Radioimmunoconjugates for the Therapy of Cancer. In: Targeted Diagnosis and Therapy J. Rodwell (ed.), Vol III Targeted Therapeutic Systems, P. Tyle and B.P. Ram (eds.), Marcel Dekker, Inc., New York, pp. 215-255

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.